How can the EU’s pharmaceutical legislation help tackle current challenges, including medicine shortages and antimicrobial resistance, across Europe? We put the question to Rainer Becker, Director for Medical Products and Innovation at DG SANTE.
The ‘entourage effect’ of cannabis comes from the pain-relieving effects of the plant, but could we boost this pain-relieving efficacy of THC without the psychoactive side effects?
David Nutt FMedSci, Chair Drug Science and PAREA, Prof of Neuropsychopharmacology at Imperial College London, explains why Europe needs to catch up with psychedelic research.
Researchers discover drug combination that could offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer.
Despite the rising incidence of Central Nervous System diseases worldwide, efficient treatment options for neurological disorders remain scarce. Treatment failures are principally associated with the inability of drugs to pass the highly selective Blood-Brain Barrier rather than a lack of efficacy.
Dr Nazneen Rahman, Founder and CEO of YewMaker and Sustainable Medicines Partnership (SMP) Director, describes why tackling wasted medicines is key to delivering a Net Zero NHS.
Cannabis legislation is threatening to reduce pharmaceutical stock value by billions of dollars as more people are predicted to opt for weed over opioids.
